Circulating poly(ADP-ribose) levels in lung cancer: an exploratory study
Monaldi Archives for Chest Disease · 13.11.2026
DOI: 10.4081/monaldi.2026.4348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Monaldi Archives for Chest Disease, online erschienen am 13.11.2026. Verfasst von Merve Alpay und 3 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Poly(ADP-ribose) (PAR) is a polymer generated during poly(ADP-ribosyl)ation, a post-translational modification involved in cellular stress responses and DNA repair. Although PAR-related pathways have been investigated in cancer biology, the clinical significance of circulating PAR levels in patients with lung cancer remains insufficiently characterized. With this study, we investigate the serum levels of PAR in patients with lung cancer and compare them with healthy individuals to assess its potential role as a prognostic biomarker. Serum samples from 23 patients with primary lung cancer who had not received prior cancer treatment and 21 healthy controls were analyzed using a commercial ELISA-based assay. Group differences were evaluated, including an analysis adjusted for age. Our findings demonstrated that the mean serum PAR levels in lung cancer patients were approximately twofold higher compared to the control group (p
Zitieren
APA
Alpay, M., Yildiz, P., Acat, M., & Sungur, M. A. (2026). Circulating poly(ADP-ribose) levels in lung cancer: an exploratory study. Monaldi Archives for Chest Disease. https://doi.org/10.4081/monaldi.2026.4348
Vancouver
Alpay M, Yildiz P, Acat M, Sungur MA. Circulating poly(ADP-ribose) levels in lung cancer: an exploratory study. Monaldi Archives for Chest Disease. 2026. doi:10.4081/monaldi.2026.4348
BibTeX
@article{Alpay2026,
author = {Alpay, Merve and Yildiz, Pinar and Acat, Murat and Sungur, Mehmet Ali},
title = {Circulating poly(ADP-ribose) levels in lung cancer: an exploratory study},
journal = {Monaldi Archives for Chest Disease},
year = {2026},
doi = {10.4081/monaldi.2026.4348}
}
EUVIMED